Exact Sciences Corp. reported record quarterly revenue of $851 million in the third quarter, an increase of 20% over the $709 million reported in the same period of 2024.
The company, a provider of cancer screening and diagnostic tests, also reported a lower net loss of $20 million, or 10 cents per share, an improvement of $19 million and 10 cents per share, respectively, over the third quarter of 2024.
The quarterly performance helped boost the company’s stock price to $69.38 per share on the Nasdaq market at Wednesday’s opening, nearly 79% above its recent low of $38.81 in August.
Exact Sciences’ revenue performance included cancer screening revenue of $666 million, an increase of 22% over the third quarter of 2024, and precision oncology revenue of $184 million, an increase of 13% over the same period a year ago.
Screening primarily includes laboratory service revenue from Cologuard and Cologuard Plus tests — both non-invasive, stool-based colorectal cancer (CRC) screening options.
Precision oncology includes laboratory service revenue from global Oncotype DX tests to uncover molecular residual disease, which refers to the presence of tumor-specific DNA in the body. These are fragments of genetic information, known as circulating tumor DNA, that are shed into the bloodstream by tumors, and their presence may indicate that cancer is present.
The company also raised full-year 2025 revenue guidance by $77.5 million to between $3.22 billion and $3.235 billion, a jump of 17%.
During the third quarter, Exact Sciences launched Cancerguard, a multi-cancer, early detection test as a laboratory-developed test — its third new product launch of 2025. To support patient access to Cancerguard, Exact Sciences recently announced an agreement with Quest Diagnostics to enable blood collection at the company’s approximately 7,000 patient access sites across the U.S.
“Exact Sciences continues to advance our mission to prevent cancer and detect it earlier through a relentless focus on patients,” Kevin Conroy, chairman and CEO, said in a press release. “Our third quarter results reflect the power of our patient-centric platform and our trusted brands, Cologuard and Oncotype DX.
“The momentum we are building is fueling growth, advancing innovative new tests like Cancerguard, and strengthening our financial performance,” Conroy said.
According to Exact Sciences, Cancerguard is the first multi-cancer early detection test commercially available that analyzes multiple biomarker classes to help detect a wide range of cancers, including those that often go undiagnosed until later stages when treatment options are limited. The Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw.
The company said its agreement with Quest Diagnostics not only enables blood collection at patient access sites, but also at in-office phlebotomists in provider offices as well as mobile phlebotomy services for at-home collections.
